Dusa Pharmaceuticals Inc. has just launched its Levulan pure form of aminolevulinic acid for use in actinic keratoses. But that hasn't deterred PhotoCure ASA from pursuing its own version of ALA for the same indication.

PhotoCure (OSE:PHO) hopes to receive Swedish marketing approval of its topically administered photodynamic therapy to treat actinic keratoses by year end. Approval in Sweden would be followed by Europe-wide approval under mutual recognition procedures. PHO plans a U.S. submission in about six months.